NEUROTOXIN COMPOSITIONS FOR USE IN TREATING HEADACHE

1 . A method for reducing the severity of a symptom associated with a migraine headache comprising:

a) administering a Clostridial neurotoxin into at least five of the muscle regions selected from the frontalis, corrugator, procerus, masseter, nasalis, oculi, occipitalis, temporalis, and trapezius muscle regions; and

b) thereby reducing the severity of the symptom associated with migraine headache.

2 . The method of claim 1 , wherein a second Clostridial neurotoxin is administered bilaterally into the Sphenopalatine Ganglion (SPG).

3 . The method of claim 1 , wherein said Clostridial neurotoxin is administered to between five and eight of the muscle regions selected from the frontalis, corrugator, procerus, masseter, nasalis, occipitalis, temporalis, trapezius and oculi muscle regions.

4 . The method of claim 1 , wherein said Clostridial neurotoxin is administered to the procerus, corrugator, occipitalis, temporalis, and trapezius muscle regions.

5 . The method of claim 1 , wherein said Clostridial neurotoxin is administered to the procerus, corrugator, occipitalis, temporalis, oculi and trapezius muscle regions.

6 . The method of claim 1 , wherein said Clostridial neurotoxin is administered to the procerus, corrugator, occipitalis, temporalis, oculi, masseter and trapezius muscle regions.

7 . The method of claim 1 , wherein said Clostridial neurotoxin is administered to the procerus, corrugator, occipitalis, temporalis, oculi, nasalis, and trapezius muscle regions.

8 . The method of claim 1 , wherein said Clostridial neurotoxin is administered to the procerus, corrugator, occipitalis, temporalis, oculi, nasalis, masseter and trapezius muscle regions.

9 . The method of claim 1 , wherein said Clostridial neurotoxin is administered to the frontalis, corrugator, occipitalis, temporalis, and trapezius muscle regions.

10 . The method of claim 1 , wherein said Clostridial neurotoxin is administered to the frontalis, corrugator, occipitalis, temporalis, oculi and trapezius muscle regions.

11 . The method of claim 1 , wherein said Clostridial neurotoxin is administered to the frontalis, corrugator, occipitalis, temporalis, oculi, nasalis, and trapezius muscle regions.

12 . The method of claim 1 , wherein said Clostridial neurotoxin is administered to the frontalis, corrugator, occipitalis, temporalis, oculi, masseter and trapezius muscle regions.

13 . The method of claim 1 , wherein said Clostridial neurotoxin is administered to the frontalis, corrugator, occipitalis, temporalis, oculi, nasalis, masseter and trapezius muscle regions.

14 . The method of claim 9 , wherein said frontalis administration is to the upper frontalis.

15 . The method of claim 1 , wherein said migraine headache is an episodic migraine or a chronic migraine.

16 . The method of claim 15 , wherein said migraine headache is an episodic migraine.

17 . The method of claim 15 , wherein said migraine headache is a chronic migraine.

18 . The method of claim 1 , wherein said Clostridial neurotoxin comprises a botulinum neurotoxin.

19 . The method of claim 18 , wherein said botulinum neurotoxins comprise botulinum type A.

20 . The method of claim 18 , wherein said botulinum neurotoxins comprise botulinum type B, C, D, E, or F.

21 . The method of claim 1 , wherein the total dose of said Clostridial neurotoxin is about 145-200 Units.

22 . The method of claim 1 , wherein the total dose of said Clostridial neurotoxin is about 195 Units.

23 . The method of claim 1 , wherein the total dose of said Clostridial neurotoxin is about 150 Units.

24 . The method of claim 1 , wherein said administration to said frontalis comprises administration of said Clostridial neurotoxin to the upper frontalis in an amount of about 10 Units at the hairline.

25 . The method of claim 1 , wherein said administration to said corrugator comprises administration of said Clostridial neurotoxin in an amount of about 10 Units.

26 . The method of claim 1 , wherein said administration to said oculi comprises administration of said Clostridial neurotoxin in an amount of about 10 Units.

27 . The method of claim 1 , wherein said administration to said temporalis comprises administration of said Clostridial neurotoxin in an amount of about 30 Units anterior to the tragus.

28 . The method of claim 1 , wherein said administration to said temporalis comprises administration of said Clostridial neurotoxin in an amount of about 60 Units anterior to the tragus.

29 . The method of claim 1 , wherein said administration to said nasalis comprises administration of said Clostridial neurotoxin in an amount of about 5 Units.

30 . The method of claim 1 , wherein said administration to said masseter comprises administration of said Clostridial neurotoxin in an amount of about 10 Units.

31 . The method of claim 1 , wherein said administration to said occipitalis comprises administration of said Clostridial neurotoxin in an amount of about 60 Units.

32 . The method of claim 1 , wherein said administration to said trapezius comprises administration of said Clostridial neurotoxin in an amount of about 30 Units.

33 . The method of claim 32 , wherein said administration to said trapezius comprises superficial administration of said Clostridial neurotoxin in an amount of about 10 Units to the superior trapezius.

34 . The method of claim 1 , wherein said procerus is not administered-to.

35 . The method of claim 1 , wherein said nasalis is not administered-to.

36 . The method of claim 1 , wherein said masseter is not administered-to.

37 . A method for reducing the severity of a symptom associated with migraine comprising:

administering a Clostridial toxin to the superior trapezius at a dosage of about 3-10 units per site at two sites on each side of the head and 5-15 units per site to the inferior trapezius at two sites on each side of the head;

administering a Clostridial toxin to the occipitalis at a dosage of about 7-15 units per site at three sites on each side of the head;

administering a Clostridial toxin to the temporalis at a dosage of about 3-15 units per site at three sites on each side of the head;

administering a Clostridial toxin to the oculi at a dosage of about 3-10 units to one site on each side of the head;

administering a Clostridial toxin to the corrugator at a dosage of about 3-10 units to one site on each side of the head;

administering a Clostridial toxin to the frontalis at a dosage of about 3-10 units to one site on each side of the head;

thereby reducing the severity of the symptom associated with migraine.

38 . A method for reducing the severity of a symptom associated with Chronic Migraine (CM) comprising:

administering a Clostridial toxin to the superior trapezius at a dosage of about 3-10 units per site at two sites on each side of the head and 5-15 units per site to the inferior trapezius at two sites on each side of the head;

administering a Clostridial toxin to the occipitalis at a dosage of about 7-15 units per site at three sites on each side of the head;

administering a Clostridial toxin to the temporalis at a dosage of about 3-15 units per site at three sites on each side of the head;

administering a Clostridial toxin to the oculi at a dosage of about 3-10 units to one site on each side of the head;

administering a Clostridial toxin to the corrugator at a dosage of about 3-10 units to one site on each side of the head;

administering a Clostridial toxin to the frontalis at a dosage of about 3-10 units to one site on each side of the head;

administering a Clostridial toxin to the nasalis at a dosage of about 1-5 units to one site on each side of the head;

administering a Clostridial toxin to the masseter at a dosage of about 3-10 units to one site on each side of the head

thereby reducing the severity of the symptom associated with CM.